Isoprostane measurement in plasma and urine by liquid chromatography-mass spectrometry with one-step sample preparation

被引:53
作者
Sircar, Debajit
Subbaiah, Papasani V.
机构
[1] Univ Illinois, Dept Med, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA
关键词
D O I
10.1373/clinchem.2006.074989
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Isoprostane F-2 alpha (iPF(2 alpha)-III) concentration in plasma and urine is widely accepted as a measure of oxidative stress. Gas chromatography-mass spectrometry (GUMS) methods for measuring iPF(2 alpha)-III involve several steps of sample preparation and are labor-intensive, and ELISA methods, although easier to use, are less reliable. Therefore we developed a simple and sensitive method involving 1-step sample cleanup and HPLC/MS quantification. Methods: Samples of plasma or urine were enriched with a deuterated (iPF(2 alpha)-III-D4) standard, treated with KOH to liberate the bound isoprostanes, then loaded onto an immunoaffinity column, and the bound isoprostane was eluted with 95% ethanol. The concentrated sample was injected onto a C-18 HPLC column, and the isoprostane was eluted with a gradient of acetonitrile in water and analyzed by electrospray negative ionization, selectively monitoring the ions 353.2 (iPF(2 alpha)-III) and 357.2 (iPF(2 alpha)-III-D4). The amount of isoprostane in the sample was calculated from the ratio of the intensities of the 2 ions. Results: The described method has a detection limit of 0.5 ng/L, with a linear dynamic range of 1-5000 ng/L. The intra- and interassay imprecisions were 4.68% and 3.88%, respectively. The values obtained correlated strongly with the GC/MS procedure (r = 0.80), but the absolute values were similar to 4- to 5-fold lower, because the present method measures specifically 1 isomer of isoprostane, whereas the GUMS method measures 4 isomers together. Conclusions: Because of its simplicity and lower limit of quantification, the present method provides a useful noninvasive tool for determining oxidative stress in patients. (c) 2007 American Association for Clinical Chemistry
引用
收藏
页码:251 / 258
页数:8
相关论文
共 21 条
[1]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[2]   Kinetics of biomarkers: biological and technical validity of isoprostanes in plasma. [J].
Coolen S.A. ;
van Buuren B. ;
Duchateau G. ;
Upritchard J. ;
Verhagen H. .
Amino Acids, 2005, 29 (4) :429-436
[3]  
Devaraj S, 2001, CLIN CHEM, V47, P1974
[4]   Isoprostanes:: Formation, analysis and use as indices of lipid peroxidation in vivo [J].
Lawson, JA ;
Rokach, J ;
FitzGerald, GA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (35) :24441-24444
[5]   Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry [J].
Lee, CYJ ;
Jenner, AM ;
Halliwell, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 320 (03) :696-702
[6]   Quantification of 8-iso-prostaglandin-F2α and 2,3-dinor-8-isoprostaglandin-F2α in human urine using liquid chromatography-tandem mass spectrometry [J].
Liang, YL ;
Wei, P ;
Duke, RW ;
Reaven, PD ;
Harman, SM ;
Cutler, RG ;
Heward, CB .
FREE RADICAL BIOLOGY AND MEDICINE, 2003, 34 (04) :409-418
[7]   An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography mass spectrometry [J].
Mori, TA ;
Croft, KD ;
Puddey, IB ;
Beilin, LJ .
ANALYTICAL BIOCHEMISTRY, 1999, 268 (01) :117-125
[8]   INCREASE IN CIRCULATING PRODUCTS OF LIPID-PEROXIDATION (F-2-ISOPROSTANES) IN SMOKERS - SMOKING AS A CAUSE OF OXIDATIVE DAMAGE [J].
MORROW, JD ;
FREI, B ;
LONGMIRE, AW ;
GAZIANO, JM ;
LYNCH, SM ;
SHYR, Y ;
STRAUSS, WE ;
OATES, JA ;
ROBERTS, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (18) :1198-1203
[9]  
Morrow JD, 1999, METHOD ENZYMOL, V300, P3
[10]   Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans [J].
Morrow, JD .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (02) :279-286